Navigation Links
AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
Date:8/14/2008

en identified for clinical screening in inoperable HCC by the institutions during 2008 and 2009. Further compounds will be made available at a rate of one per year, for the duration of the partnership, which is in place until 2012.

Professor Soo Khee Chee, NCCS Director and Assistant CEO (Research and Education) of SingHealth, said: "NCCS has a very active research programme run by high quality scientists who have produced some significant outcomes in liver cancer research. This collaboration will give our researchers and clinician scientists another opportunity to make a positive contribution that can benefit all cancer patients. Because of our wide patient base, our teams are better exposed and experienced in all types of cancer. Our large base has allowed us to carry out meaningful and effective clinical trials."

Pre-clinical activities are also included in the partnership, under the terms of which the same institutions will be given annual access to up to six novel candidate drugs for appraisal of activity in the mouse in vivo primary HCC explant model.(4)

For both clinical and pre-clinical activities, AstraZeneca retains the option to assume further development and marketing of all drugs made available as part of the partnership deal.

"This partnership with AstraZeneca is testament to the standard and quality of research in Singapore. We will work closely together to develop new anti-cancer therapies for Asian patients through access to some of AstraZeneca's clinical and pre-clinical compounds and world-class training of our researchers at MCRC," said Associate Professor Goh Boon Cher, Senior Consultant, Dept of Haematology-Oncology, National University Hospital.

Notes to Editors:

AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's l
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
2. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
3. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
10. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "MEMS Gyroscopes Analog Devices ADIS16136 ... report to their offering. ... tactical grade applications made a lot of progress ... reliability. They are now accepted in high-reliability environments, ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ... Vena Cava (IVC) Filters - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior ... US$435 million by 2016. The North America ... global value while Europe claims ...
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2
... Inc. (Nasdaq: AUXL ) today announced that ... 31st Annual Health Care Conference during March 7-9, 2011 ... Chief Financial Officer, is scheduled to present an overview ... a.m. ET on Wednesday, March 9, 2011.   ...
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 3Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... Beltsville, MD (PRWEB) December 15, 2014 ... and services today released “ Social Media Cheat Sheets ... cultivating a community that drives results on the top ... a marketing program. It helps drive awareness, engagement, and ... conversions. For marketers to make an impact on new ...
(Date:12/15/2014)... 14, 2014 (HealthDay News) -- Expert pilots process visual ... why they make better decisions during landings, a new ... difficult techniques for pilots to master, and 36 percent ... crashes occur during final approach and landing. Researchers ... 12 moderately experienced pilots while they were at the ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device ... North and South America, Europe, the Middle East, Asia ... for its 2015 Medical Device Industry Survey. Each year, ... business and market trends as well as regulatory and ... areas including:, , Overall prospects for ...
Breaking Medicine News(10 mins):Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... News) -- People are more likely to recall an unpleasant experience ... over than if they expect it to occur again, say researchers. ... enjoyable whether they think they,ll do them again or not. ... they have a bad experience and allow them to be pleasantly ...
... Researchers at St. Michael,s Hospital and the Institute for ... new tool that will help doctors predict the probability of ... study, published in the journal Circulation , found that ... 30 days and one year after an ischemic stroke. An ...
... 2011Canadians living in deprived neighbourhoods are twice as likely to ... Pacific Coast, according to a new study by researchers at ... rates of illness and death are significantly higher in poorer ... plays a big role in how strongly they are affected," ...
... Simply looking at your body reduces pain, according to new research ... Milano-Bicocca, Italy. Published in the journal Psychological ... pain experienced when a hot object touches the skin. ... looked the larger the hand the greater the effect of ...
... HealthDay Reporter , WEDNESDAY, Feb. 9 (HealthDay News) -- Surgery ... cord birth defect known as spina bifida may be most ... groundbreaking -- research suggests. When successful, the surgery could ... not, experts say, since twice as many spina bifida-affected children ...
... FRANCISCO (February 10, 2011) In a study to ... (SMFM) annual meeting, The Pregnancy Meeting , in San ... intake before and during pregnancy does not protect Norwegian ... has been studied as a possible protecting factor against ...
Cached Medicine News:Health News:New online tool predicts probability of death from stroke 2Health News:Coastal Canadians living in high-risk neighborhoods in poorer health: Study 2Health News:Look at your body to reduce pain 2Health News:Fetal Surgery Could Boost Outcomes in Severe Spina Bifida 2Health News:Fetal Surgery Could Boost Outcomes in Severe Spina Bifida 3Health News:Fetal Surgery Could Boost Outcomes in Severe Spina Bifida 4Health News:Study finds that folate does not offer protection against preterm delivery 2
... most powerful isolated ESU on the market with ... the only ESU that allows the surgeon to ... a standard ES pencil. Excalibur Plus PC Patented ... voltage for smooth cutting through various impedance tissues ...
The Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Maddox rod and occluder...
9 inch double ended with one end black and the other end with 49 holes...
Medicine Products: